Innova Captab Ltd
Healthcare | Small Cap
Innova Captab Ltd shows a strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits while maintaining very healthy margins and returns for its investors. Its financial stability is a key strength, as it operates with very little debt, reducing risks associated with borrowing. This allows the company to reinvest its earnings back into the business. A notable area of focus is the company's operational efficiency; while it is growing its assets significantly, turning those assets into revenue is a developing aspect. It also takes a considerable amount of time to collect payments from customers. The future outlook appears positive, driven by aggressive growth strategies, though it is dependent on the successful utilization of its substantial new investments.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio6.80
- Profitability Ratio10.00
- Efficiency Ratio3.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio5.86
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Innova Captab Ltd shows a strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits while maintaining very healthy margins and returns for its investors. Its financial stability is a key strength, as it operates with very little debt, reducing risks associated with borrowing. This allows the company to reinvest its earnings back into the business. A notable area of focus is the company's operational efficiency; while it is growing its assets significantly, turning those assets into revenue is a developing aspect. It also takes a considerable amount of time to collect payments from customers. The future outlook appears positive, driven by aggressive growth strategies, though it is dependent on the successful utilization of its substantial new investments.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
64.90
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
38.55
P/B RATIO
4.97
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
3.33
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
1.18
EV/EBITDA RATIO
22.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹949.55 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤2nd Feb 26
Q3 & 9M FY26 Earnings Conference Call
BULLISH SENTIMENT
The company is in a phase of exceptional and robust expansion. It is achieving outstanding growth in revenue, operating profits, and net income, indicating strong market demand and effective operational scaling. This high growth is supported by a significant increase in the company's asset base, reflecting aggressive investment in its future. The earnings available to each shareholder are also growing at an excellent rate, signaling that this expansion is creating substantial value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 94.89 | 15.61 | 16.74 | 15.08 | 31.03 |
| Operating Profit Growth Rate | 77.78 | 18.75 | 35.09 | 20.78 | 30.65 |
| Earnings Per Share (EPS) Growth | 85.36 | -97.34 | 16.45 | 35.9 | 9.91 |
| Asset Growth Rate | 55.41 | 22.43 | 86.93 | 19.15 | 17.16 |
| Net Income Growth Rate | 88.24 | 6.25 | 38.24 | 36.17 | 10.16 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial strategy is clearly focused on long-term growth over short-term shareholder payouts. It is generating excellent earnings and cash flow per share, and its intrinsic book value is increasing impressively. However, this value is being retained within the company, as it does not pay dividends and is channeling a very large amount of cash into capital expenditures. This reflects an aggressive reinvestment strategy aimed at expanding its operational base for future returns.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 53.33 | 13.75 | 16.49 | 22.46 | 24.74 |
| Cash Earnings Per Share (Cash EPS) | 60 | 16.46 | 19.3 | 26.84 | 32.63 |
| Book Value Per Share | 174.17 | 57.71 | 145.79 | 168.25 | 191.4 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 80 | 78 | 287 | 172 | 61 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is exceptional across all key measures. It demonstrates a superior ability to control costs, resulting in strong margins from its sales. More importantly, it is highly effective at generating high returns on the money invested by both shareholders and lenders, as well as on its entire asset base. This all-around excellent performance in turning revenue and capital into profit indicates a highly efficient and well-managed business with a strong competitive advantage.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 10.99 | 11.12 | 12.77 | 12.94 | 12.15 |
| Return on Capital Employed (ROCE) | 31 | 24 | 19 | 15 | 15 |
| Return on Equity (ROE) | 30.62 | 24.55 | 11.31 | 13.35 | 12.92 |
| Return on Assets (ROA) | 16.7 | 16.19 | 11.7 | 11.86 | 13.23 |
| Operating Margin | 11.99 | 12.31 | 14.25 | 14.95 | 14.91 |
| Net Margin | 7.99 | 7.34 | 8.7 | 10.29 | 8.65 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's overall operational efficiency presents a mixed picture with some notable challenges. While it manages its inventory at an acceptable speed, there are difficulties in other key areas. The company is not generating a high volume of sales from its investments in fixed and total assets, suggesting these resources may be underutilized. Additionally, it takes a relatively long time to collect payments from its customers, which can tie up cash. These factors point to areas where operational performance is lagging.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 4.38 | 5.06 | 3.02 | 1.5 | 1.94 |
| Inventory Turnover Ratio | 6.5 | 6.73 | 7.23 | 6.15 | 5.83 |
| Receivables Turnover Ratio | 4.55 | 3.87 | 3.91 | 4.01 | 4.24 |
| Days Sales in Inventory Ratio | 56.15 | 54.23 | 50.48 | 59.35 | 62.61 |
| Receivable Days | 80.22 | 94.32 | 93.35 | 91.02 | 86.08 |
| Capital Turnover Ratio | 2.89 | 2.53 | 1.04 | 1.03 | 1.25 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations is strong in some areas but reflects its strategic choices in others. Its earnings are more than sufficient to handle its interest payments, which is a very positive sign of financial health. On the other hand, the company is not currently paying dividends. This indicates a policy of retaining all profits, likely to fund its aggressive growth and expansion plans, rather than distributing them to shareholders.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 15.33 | 5.6 | 7.19 | 86.5 | 12.06 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits exceptional long-term financial stability. Its reliance on debt is extremely low, with the vast majority of its assets being funded by equity. This conservative financial structure significantly reduces the risk associated with interest payments and loan repayments, making the company highly resilient to economic downturns and rising interest rates. Stakeholders can view this as a sign of a very strong and secure financial foundation, with minimal risk of bankruptcy due to debt.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.25 | 0.33 | 0.2 | 0.2 | 0.17 |
| Debt to Equity Ratio | 0.33 | 0.49 | 0.25 | 0.25 | 0.2 |
| Equity Ratio | 0.75 | 0.67 | 0.8 | 0.8 | 0.83 |
| Debt To Asset Ratio | 0.12 | 0.19 | 0.16 | 0.16 | 0.12 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company demonstrates a satisfactory ability to meet its short-term financial obligations. It holds enough current assets to cover immediate liabilities, indicating a degree of financial flexibility. However, its reliance on turning inventory and receivables into cash is notable, as its immediate cash reserves and cash generated from operations are less robust. This suggests a manageable but tight balance in its day-to-day financial management, where its ability to sell products and collect payments is crucial for maintaining liquidity.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.32 | 1.71 | 2.25 | 1.97 | 1.77 |
| Quick Ratio | 0.89 | 1.31 | 1.73 | 1.4 | 1.24 |
| Cash Ratio | 0.01 | 0.07 | 0.32 | 0.19 | 0.01 |
| Operating Cash Flow Ratio | 0.2 | 0.23 | 0.53 | 0.18 | 0.22 |
Current Ratios
Quick Ratios
Cash Ratios
Operating Cash Flow Ratios
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 12 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
Management effectiveness presents a mixed profile. The company demonstrates strong execution on growth, with robust multi-year sales and profit expansion, stable operating margins, and efficient working capital management. This is further supported by a significant increase in institutional shareholding and a much-improved debt-to-equity ratio following a recent capital infusion. However, these strengths are counterbalanced by significant weaknesses in capital efficiency. Key return metrics like ROCE and ROE are on a clear downward trend, and asset turnover has weakened considerably. The policy of zero dividend payout and volatile interest coverage also weigh on the assessment, indicating that while growth is being pursued aggressively, profitability on invested capital is deteriorating.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (5Y) | 32% | strong |
| Compounded Profit Growth (5Y) | 33% | strong | |
| Debt/Equity Ratio (Mar 2024) | 0.29 | improving | |
| DII Holding (Dec 23 -> Mar 24) | 10.31% -> 20.78% | very strong | |
| CONS | ROCE % (Mar 2022 -> Mar 2024) | 31% -> 19% | declining |
| Return on Equity (Last Year) | 14% | weak | |
| Asset Turnover (Mar 2023 -> Mar 2024) | 1.31 -> 0.82 | declining | |
| Dividend Payout % | 0% | poor |
Financial Performance & Growth
The company exhibits strong financial performance driven by consistent growth in revenue and profitability. Over the past five years, sales have compounded at a rate of 32%, with profit growth at 33%. This momentum includes a robust 42% increase in net profit in the most recent fiscal year (FY24) on 17% sales growth, recovering from a slower prior year. Operating profit margins have remained stable, fluctuating within a 12-14% range annually, suggesting effective control over operational costs while scaling the business. The quality of earnings is sound, with core operations being the primary profit driver; 'Other Income' constituted only 9.2% of profit before tax in FY24.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Sales Growth % | 94.9% | 15.7% | 16.7% |
| Profit Growth % | 86.0% | 4.0% | 42.0% |
| OPM % | 12.0% | 12.0% | 14.0% |
Capital Efficiency & Returns
A significant concern is the deteriorating capital efficiency and shareholder returns. The Return on Capital Employed (ROCE) has been on a consistent decline, falling from a peak of 31% in March 2022 to 19% by March 2024. This indicates that each unit of capital invested is generating progressively lower profits. Similarly, the Return on Equity (ROE) shows a weakening trend, with the most recent year's figure at 14%. This decline in profitability is further explained by a sharp drop in the Asset Turnover ratio, which fell from 1.31 in FY23 to 0.82 in FY24. This implies that the company's significantly expanded asset base, particularly from capital work in progress, is not yet generating a proportional increase in sales, highlighting an issue in asset utilization.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| ROCE % | 31% | 24% | 19% |
| ROE (Last Year) % | 15% | 15% | 14% |
| Asset Turnover | 1.39 | 1.31 | 0.82 |
Financial Health & Prudence
The company's financial health has shown marked improvement, primarily due to capital management following its IPO. The Debt-to-Equity ratio saw a significant reduction, dropping from 0.86 in March 2023 to a more comfortable 0.29 in March 2024, strengthening the balance sheet and reducing financial risk. The company has also demonstrated efficiency in managing its working capital, as evidenced by a stable Cash Conversion Cycle, which stood at 75 days in the latest period. However, a point of caution is the volatility in the Interest Coverage Ratio. It declined from 15.3 in FY22 to 5.6 in FY23 before recovering to 7.2 in FY24. The company maintains a consistent policy of a 0% dividend payout, retaining all earnings for reinvestment.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Debt/Equity Ratio | 0.95 | 0.86 | 0.29 |
| Interest Coverage Ratio | 15.3x | 5.6x | 7.2x |
| Cash Conversion Cycle | 87 | 77 | 75 |
Shareholding & Ownership Structure
The ownership structure signals strong alignment and growing institutional confidence. Promoter holding has remained stable at 50.90%, indicating continued commitment. The most compelling evidence is the sharp increase in Domestic Institutional Investors (DIIs) holding, which more than doubled from 10.31% in December 2023 to 20.78% in March 2024. This substantial inflow from professional fund managers represents a strong vote of confidence in the company's strategy and future prospects. While Foreign Institutional Investors (FIIs) reduced their stake in the same period, the DIIs' aggressive buying led to a net increase in overall institutional ownership from 13.88% to 22.72%, which is a strong positive indicator.
| Shareholding (%) | Dec 2023 | Mar 2024 |
|---|---|---|
| Promoters | 50.90% | 50.90% |
| FIIs | 3.57% | 1.94% |
| DIIs | 10.31% | 20.78% |
| Total Institutional | 13.88% | 22.72% |
The primary risk stems from the company's aggressive capital expenditure, which has led to consistently negative free cash flow over the past three years. The cash outflow for investments far exceeds the cash generated from operations, creating a reliance on external financing activities to fund growth ambitions. While the company's recent IPO has bolstered its cash position and reduced debt, this high-capex strategy is also a likely cause of declining capital efficiency ratios (ROCE, ROE). This combination of negative cash flow and weakening return metrics presents a moderate risk, indicating that while the company is investing for the future, it is in a financially intensive and vulnerable phase.
Free Cash Flow Strain
A significant red flag is the company's consistently negative Free Cash Flow (FCF). For the fiscal years ending March 2022, 2023, and 2024, the FCF was -₹21 Cr, -₹11 Cr, and -₹141 Cr, respectively. This trend indicates that capital expenditures are substantially outpacing the cash generated from core business operations. The cash flow statement reveals that 'Cash from Investing Activity' has been heavily negative, driven by large asset purchases and acquisitions. While Cash Flow from Operations (CFO) is healthy and growing, it is insufficient to cover these large investments, forcing a reliance on 'Cash from Financing Activity' to bridge the gap. This pattern highlights a risk of cash burn and financial dependency to fuel its growth strategy.
| Metric (₹ Cr) | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Cash from Operations | 59 | 67 | 146 |
| Cash from Investing | -188 | -91 | -499 |
| Free Cash Flow | -21 | -11 | -141 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10944.43Bullish
- SMA 20938.92Bullish
- SMA 50947.53Bullish
- EMA 10945.58Bullish
- EMA 20943.77Bullish
- EMA 50937.26Bullish
- DEMA 10949.38Bullish
- DEMA 20945.16Bullish
- DEMA 50954.09Bearish
- TEMA 10952.42Bearish
- TEMA 20945.37Bullish
- TEMA 50949.28Bullish
- MACD1.63Bullish
- ADX19.76Weak Trend
- IndicatorValueSignal
- RSI54.76Neutral
- CCI81.32Neutral
- ROC 93.32Bullish
- ROC 141.20Bullish
- ROC 25-1.21Bearish
- Stoch K83.41Overbought
- Stoch D82.90Overbought
- IndicatorValueSignal
- BB Upper961.86Neutral
- BB Middle938.92Neutral
- BB Lower915.99Neutral
- ATR10.85Low Volatility
- IndicatorValueSignal
- MFI64.42Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10938.98Bullish
- SMA 20946.73Bullish
- SMA 50920.94Bullish
- EMA 10944.31Bullish
- EMA 20942.15Bullish
- EMA 50923.82Bullish
- DEMA 10945.37Bullish
- DEMA 20949.83Bullish
- DEMA 50955.02Bearish
- TEMA 10946.65Bullish
- TEMA 20943.19Bullish
- TEMA 50957.89Bearish
- MACD4.92Bearish
- ADX32.70Strong Trend
- IndicatorValueSignal
- RSI56.01Neutral
- CCI28.41Neutral
- ROC 91.28Bullish
- ROC 14-0.96Bearish
- ROC 25-0.39Bearish
- Stoch K60.82Neutral
- Stoch D59.77Neutral
- IndicatorValueSignal
- BB Upper972.09Neutral
- BB Middle946.72Neutral
- BB Lower921.36Neutral
- ATR16.23Low Volatility
- IndicatorValueSignal
- MFI33.61Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10946.40Bullish
- SMA 20934.60Bullish
- SMA 50890.92Bullish
- EMA 10942.33Bullish
- EMA 20930.28Bullish
- EMA 50893.96Bullish
- DEMA 10949.95Bullish
- DEMA 20955.42Bearish
- DEMA 50952.04Bearish
- TEMA 10944.33Bullish
- TEMA 20956.10Bearish
- TEMA 50N/AN/A
- MACD17.91Bearish
- ADX41.78Strong Trend
- IndicatorValueSignal
- RSI58.95Neutral
- CCI47.96Neutral
- ROC 90.17Bullish
- ROC 144.94Bullish
- ROC 2510.81Bullish
- Stoch K55.67Neutral
- Stoch D49.38Neutral
- IndicatorValueSignal
- BB Upper984.59Neutral
- BB Middle934.60Neutral
- BB Lower884.61Neutral
- ATR27.02Low Volatility
- IndicatorValueSignal
- MFI80.28Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10931.76Bullish
- SMA 20894.07Bullish
- SMA 50830.50Bullish
- SMA 100759.87Bullish
- SMA 200769.40Bullish
- EMA 10928.90Bullish
- EMA 20904.17Bullish
- EMA 50846.08Bullish
- EMA 100801.76Bullish
- EMA 200788.30Bullish
- DEMA 10952.92Bearish
- DEMA 20948.26Bullish
- DEMA 50919.17Bullish
- DEMA 100845.03Bullish
- DEMA 200792.70Bullish
- TEMA 10954.12Bearish
- TEMA 20952.15Bearish
- TEMA 50955.44Bearish
- TEMA 100905.54Bullish
- TEMA 200811.13Bullish
- MACD33.01Bullish
- ADX31.32Strong Trend
- IndicatorValueSignal
- RSI67.20Neutral
- CCI86.56Neutral
- ROC 1410.31Bullish
- ROC 258.91Bullish
- Stoch K72.47Neutral
- Stoch D76.00Neutral
- IndicatorValueSignal
- BB Upper978.82Neutral
- BB Middle894.06Neutral
- BB Lower809.31Neutral
- ATR37.66Low Volatility
- IndicatorValueSignal
- MFI87.86Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20750.72Bullish
- SMA 50785.84Bullish
- EMA 20789.38Bullish
- EMA 50778.17Bullish
- DEMA 20826.73Bullish
- DEMA 50780.65Bullish
- TEMA 20880.14Bullish
- TEMA 50N/AN/A
- MACD36.01Bullish
- ADX25.83Strong Trend
- IndicatorValueSignal
- RSI64.66Neutral
- CCI110.16Overbought
- ROC 1438.62Bullish
- ROC 2536.74Bullish
- Stoch K83.42Overbought
- Stoch D80.03Overbought
- IndicatorValueSignal
- BB Upper921.21Overbought
- BB Middle750.72Neutral
- BB Lower580.24Neutral
- ATR68.58High Volatility
- IndicatorValueSignal
- MFI71.62Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6729.31Bullish
- SMA 12787.36Bullish
- SMA 24804.51Bullish
- EMA 6765.74Bullish
- EMA 12769.75Bullish
- EMA 24742.36Bullish
- DEMA 6768.58Bullish
- DEMA 12767.31Bullish
- DEMA 24N/AN/A
- TEMA 6795.21Bullish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX29.89Strong Trend
- IndicatorValueSignal
- RSIN/AN/A
- CCIN/AN/A
- ROC 2579.75Bullish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper1072.21Neutral
- BB Middle836.79Neutral
- BB Lower601.38Neutral
- ATR140.55High Volatility
- IndicatorValueSignal
- MFI52.62Neutral